# Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma

> **NCT04107103** · PHASE2 · COMPLETED · sponsor: **AHS Cancer Control Alberta** · enrollment: 6 (actual)

## Conditions studied

- SCCHN

## Interventions

- **DRUG:** Combination Product: Nivolumab with Pemetrexed

## Key facts

- **NCT ID:** NCT04107103
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-19
- **Primary completion:** 2023-04-14
- **Final completion:** 2023-04-28
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04107103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04107103, "Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04107103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*